Company profile
GALMED PHARMACEUTICALS LTD.
NASDAQ:GLMDBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ARAMCHOL MEGLUMINE | phase2 | — | 12 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (15)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04104321 | phase3 | suspended | 2019-09-23 | 2022-12-08 | Galmed Research and Development, Ltd. | A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR) |
| NCT02279524 | phase2 | completed | 2015-04-29 | 2018-05-22 | Galmed Research and Development, Ltd. | A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH |
| NCT05857215 | phase1 | completed | 2021-03-05 | 2021-07-01 | Galmed Pharmaceuticals Ltd | A First-in-Human Study of Single and Multiple Doses of Amilo-5MER in Healthy Subjects |
| NCT00776841 | phase1 | completed | 2008-09-01 | 2009-09-01 | Galmed Medical Reserch | A Phase 1 Single and Multiple-Dose Study of Aramchol in Healthy Male Volunteers |
| NCT06095986 | phase2 | withdrawn | 2025-06-01 | 2026-09-01 | Galmed Pharmaceuticals Ltd | A Study Evaluating the Safety, Tolerability, and Efficacy of Aramchol Meglumine in Primary Sclerosing Cholangitis |
FDA applications (0)
No records yet.